Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/118—Prognosis of disease development
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/158—Expression markers
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

• the present invention falls in general within the field of biomedicine and in particular refers to a method for the diagnosis and / or prognosis of acute renal damage.
• NTA Acute Tubular Necrosis
• FRA markers such as NGAL, IL18, KIM, Cystatin C, VEGF or CXCL10, which seem to function as good markers in child populations without significant added pathologies but not in adult population (Vaidya et al., 2008).
• Renal ischemia, hypovolemia and toxic are the most frequent causes of NTA development.
• tissue hypoxia cause damage at the level of the proximal tubular epithelium, cause a rapid decrease of the glomerular filtration rate, alter vascular permeability and trigger an inflammatory response that amplifies tissue damage (Thurman et al., 2007).
• the extent and extent of ischemic damage are dependent on the severity and duration of ischemia. In sublethal ischemia, detachment of the cells of the proximal epithelium, many of them viable, is observed in the tubular lumen.
• the miRNAs are small size RNAs (22-25 nucleotides) endogenously encoded capable of recognizing messenger RNAs and thus negatively regulate protein expression, within induced silencing complexes (RISC) by total or partial complementarity with their target mRNA (Chang and Mendell, 2007).
• RISC induced silencing complexes
• more than 700 have already been cloned and bioinformatic predictions indicate that all of them can control the expression of more than 30% of total proteins (Filipowicz et al., 2008). Most are transcribed by RNA Pol II from individual genes or from polycistronic transcripts for several of them at once.
• miRNAs are also key regulators in the rapid and precise cellular response to any type of stimulus including lack of nutrients or hypoxia (Ivan et al., 2008).
• these miRNAs together with mRNAs can be secreted or exchanged by cells in the form of microparticles (platelet microvesicles; tumor cell exosomes; neutrophil ectosomes (Valadi et al., 2007). could be detected in body fluids such as blood, urine or pleural fluid.
• body fluids such as blood, urine or pleural fluid.
• the peripheral blood of healthy individuals may contain a concentration between 5-50 mg / ml of microparticles, which would increase in case of patients with various pathologies ( Hunter et al., 2008) This would allow a very reliable monitoring of the evolution of these pathologies using samples obtained by minimally invasive methods (blood collection and urine collection (Gilad 2008).
• the detected miRNAs In urine, the detected miRNAs, among the that the miR-127 is found, have shown great stability, even in very aggressive conditions (Melkonyan et al., 2008). Since the deregulation of m iRNAs can cause various pathologies, these are beginning to be considered as new therapeutic action targets. In fact, tools have been developed to modulate their expression: pre-mirs to overexpress them and antagomirs (anti-mirs) to inhibit them, with very encouraging results in various experimental models in vitro and in vivo (Krutzfeld et al., 2006; Care et al., 2007; Van Rooij et al., 2008), although its validity as a therapeutic strategy in humans is yet to be determined.
• miRNAs in response to ischemia, their expression in focal cerebral ischemia in rat has been determined, establishing an association between miR-145 expression and brain damage (Dharap et al., 2009).
• miR-100 and miR-133 appear to participate in the mechanism of cardiac damage (Sucharov C, et al., 2008).
• miR-223 In liver ischemia also in humans, miR-223 has been established as a damage mediator (Yu et al., 2008).
• miR-126 and miR-210 have been described as fundamental promoters of angiogenesis, neovascularization and tissue repair in response to various stimuli, including hypoxia (Suarez and Sessa, 2009; Fasanaro et al., 2008; van Solingen et al., 2008).
• miRNAs modulated in renal l / R have not been described in the literature, but they do start to speculate with their potential as biomarkers in renal pathologies, including those that lead to alterations in the regulation of tension arterial (Liang M et al., 2009).
• some miRNAs related to immune rejection in renal transplantation have been identified (Sui et al., 2008). All of the above justifies the need to identify and validate new biomarkers of renal damage evolution more precise and indicative of which tissue compartment and to what extent it is being damaged and / or recovering, whose determination is also fast, simple and without biopsy. to the patient.
• the present invention provides a method for the diagnosis and / or prognosis of acute renal damage comprising analyzing a sample obtained from a patient, to determine the level of expression of at least one micro-RNA selected from between miR-127, miR-126, miR-210 and miR-101 and compare said level of expression with a control value, where the alteration of said level is indicative of renal damage.
• the sample of the patient to be analyzed is blood.
• the sample is serum.
• the sample is urine.
• the diagnosis and / or prognosis of acute renal damage is carried out by determining the level of expression of miR-127 only or in combination with at least one micro-RNA selected from miR-126, miR- 210 and miR-101.
• the decrease in the level of expression of miR-127 in serum with respect to the control value is indicative of acute renal damage.
• the increase in the level of expression of miR-127 in urine with respect to the control value is indicative of acute renal damage.
• the diagnosis and / or prognosis of acute renal damage is carried out by determining the level of expression of miR-126 alone or in combination with at least one micro-RNA selected from miR-127, miR- 210 and miR-101.
• the decrease in the level of expression of miR-126 in serum with respect to the control value is indicative of acute renal damage.
• the diagnosis and / or prognosis of acute renal damage is carried out by determining the expression level of miR-210 alone or in combination with at least one micro-RNA selected from miR-127, miR- 126 and miR-101.
• the increase in the level of expression of miR-210 in serum with respect to the control value is indicative of acute renal damage.
• the decrease in the level of expression of miR-210 in urine with respect to the control value is indicative of acute renal damage.
• the diagnosis and / or prognosis of acute renal damage is carried out by determining the level of expression of miR-101 alone or in combination with at least one micro-RNA selected from miR-127, miR- 126 and miR-210.
• the increase in the level of expression of miR-101 in serum with respect to the control value is indicative of acute renal damage.
• acute renal damage refers to renal damage that has either primary or secondary ischemic etiology, as is the case of renal damage by toxic or radiocontrast means, and in any case, excluding chronic renal damage.
• the expression of the micro-RNA is determined by PCR. In a more particular aspect, the expression of the micro-RNA is determined by quantitative PCR. In a more particular aspect, the expression of micro-RNA is determined by multiplex PCR.
• the expression of the micro-RNA is determined by total RNA microarrays.
• the present invention relates to a kit for the diagnosis and / or prognosis of acute renal damage comprising the probes and primers necessary to carry out the method of the present invention.
• the kit comprises the probes and primers necessary to determine the level of expression of at least one micro-RNA selected from miR-127, miR-126, miR-210 and miR-101 .
• the kit comprises an RNA microarray.
• Figure 1 shows the expression of miR-126 in HK-2 human proximal tubular cells submitted to the Hypoxia / Reoxygenation protocol: NX: cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (medium complete 10% FBS) CC: control cells that have undergone nutrient restriction (they are in the middle without nutrients). Hyp: cells that have undergone nutrient and oxygen restriction for 6h (1% oxygen in medium without nutrients); R-3, R-6, R-24h: cells that after 6 hours of hypoxia return to normal conditions of availability of oxygen and nutrients.
• Figure 2 shows the expression of miR-210 in HK-2 human proximal tubular cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-3, R-6, R-24h cells that return to normal conditions of availability of oxygen and nutrients.
• Figure 3 shows the expression of miR-101 in HK-2 human proximal tubular cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-3, R-6, R-24h cells that return to normal conditions of availability of oxygen and nutrients.
• Figure 4 shows the expression of miR-127 in HK-2 human proximal tubular cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R- 3, R-6, R-24h cells that return to normal conditions of availability of oxygen and nutrients.
• Figure 5 shows the expression of miR-101 in rat proximal tubular cells NRK-52E submitted to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients); R-15 min, R-30 min, R-1 h, R-3h, R-6h, R-24h: cells that return to normal conditions of oxygen and nutrient availability.
• Figure 6 shows the expression of miR-127 in rat proximal tubular cells NRK-52E submitted to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients); R-15 min, R-30 min, R-1 h, R-3h, R-6h, R-24h: cells that return to normal conditions of oxygen and nutrient availability.
• Figure 7 shows the expression of miR-101 in human HMEC endothelial cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-15 min, R-30 min, R-1 h, R-3h, R-24h cells that return to normal conditions of oxygen and nutrient availability.
• Figure 8 shows the expression of miR-127 in human HMEC endothelial cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-15 min, R-30 min, R-1 h, R-3h, R-24h cells that return to normal conditions of oxygen and nutrient availability.
• Figure 9 shows the expression of miR-210 in human HMEC endothelial cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-15 min, R-30 min, R-1 h, R-3h, R-24h cells that return to normal conditions of oxygen and nutrient availability.
• Figure 10 shows the expression of miR-126 in human HMEC endothelial cells subjected to the Hypoxia / Reoxygenation protocol.
• NX cells under normal conditions in terms of oxygen availability (normoxia, 21%) and nutrient availability (complete medium 10% FBS)
• CC control cells that have undergone nutrient restriction (they are in the middle without nutrients).
• Hyp cells that have suffered restriction of nutrients and oxygen (1% of oxygen in medium without nutrients);
• R-15 min, R-30 min, R-1 h, R-3h, R-24h cells that return to normal conditions of oxygen and nutrient availability.
• Figure 11 shows the expression of miR-127 in serum of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data.
• Oh, and 3 days times in which the patient's sample has been taken, upon entering by FRA (Oh) and later in its evolution (3 days).
• Figure 12 shows the expression of miR-127 in urine of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data.
• Oh, and 3 days times in which the patient's sample has been taken, upon entering by FRA (Oh) and later in its evolution (3 days).
• Figure 13 shows the expression of miR-126 in serum of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data.
• Oh, and 3 days times in which the patient's sample has been taken, upon entering by FRA (Oh) and later in its evolution (3 days).
• Figure 14 shows the expression of miR-210 in serum of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data. Day 0, Day 1, Day 2, Day 3, Day 7: times in which the patient's sample was taken, upon entering by FRA (day 0) and later in its evolution.
• Figure 15 shows the expression of miR-210 in urine of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data. Day 0, Day 1, Day 2, Day 3, Day 7: times in which the patient's sample was taken, upon entering by FRA (day 0) and later in its evolution.
• Figure 16 shows the expression of miR-101 in serum of patients diagnosed with Acute Renal Failure (ARF) of ischemic etiology.
• Control miRNA expression in healthy control equal to 1.
• the expression data in the patient is relativized to this data.
• Figure 17 shows the expression of miR-101 in serum samples a: in patients belonging to group IA, b: in patients belonging to group IB, and c: in patients belonging to group II.
• Figure 18 shows the expression of miR-127 in serum samples a: in patients belonging to group IA, b: in patients belonging to group IB, and c: in patients belonging to group II.
• Figure 19 shows the expression of miR-126 in serum samples a: in patients belonging to group IA, b: in patients belonging to group IB, and c: in patients belonging to group II.
• Figure 20 shows the expression of miR-210 in serum samples a: in patients belonging to group IA, b: in patients belonging to group IB, and c: in patients belonging to group II. Detailed description of the invention
• micro-RNAs miR-127, miR-126, miR-210 and miR-101 in an H / R model that mimics l / R, were expressed in a way differential so that each of these micro-RNAs alone or together serves as biomarkers of kidney damage.
• EXAMPLE 1 Expression of miRNAs in cell lines undergoing hypoxia / reoxyqenation.
• HK2 human proximal tubular cells
• NRK-52E rat proximal tubular cells
• HMEC human microvasculature endothelial cells
• hypoxia in an airtight incubator at 37 5 C, perfused with a mixture of 5% C02, 1% 02, 94% N2; reoxygenation, in a standard incubator at 37 5 C, with 5% C02.
• the cells were grown to confluence and deprived of serum 24 hours before hypoxia. During hypoxia, they were kept in minimal medium (HBSS) without serum, with low concentration of glucose or derivatives. During reoxygenation a complete medium was used (Sáenz-Morales et al., 2006). The hypoxia time for all samples was 6h, and the reoxygenation times were variable (15 min-72h). All in vitro experiments were repeated at least 3 times.
• the expression of the different micro-RNAs in the cell lines was determined by PCR, for this purpose and after extracting the total RNA from the fluid samples (serum or urine) and assessing it, 50 nanograms of each of them were used.
• RT retrotranscription reaction
• Special commercial primers seed loop primers
• These primers were specific for each miRNA.
• qPCR quantitatively (qPCR). In this reaction, which was carried out in a total volume of 10 microliters, I microliter of the total RT reaction and specific primers for each miRNA was used and also a Taqman probe with fluorescence traps.
• miR-210 expression levels like miR-126, were very dependent on the availability of nutrients and oxygen, since the restriction of both decreased their expression very significantly with respect to the condition normal
• the expression of the miRNA was recovered at the time of reoxygenation, where the cells returned to have oxygen and nutrients.
• the decrease in miR-210 indicated lack of nutrients and oxygen in proximal tubular cells, being indicative, as in the case of miR-126, of renal ischemia.
• epithelial damage was recorded in vitro, the low expression of miR-210 indicated damage to the tubular proximal epithelium after ischemia.
• miR-101 increased its expression in the hypoxia condition, compared to the normoxia condition.
• the expression of this miRNA was normalized again in reoxygenation where the availability of oxygen and nutrients was normalized again.
• the increased expression of this miRNA in proximal cells during the hypoxia condition was indicative of renal ischemia.
• miR-127 increased its expression in the hypoxia condition compared to the normoxia condition.
• the expression of this miRNA decreased significantly in reoxygenation, increasing again after 24 hours of reoxygenation when the epithelial monolayer is recovering.
• the increased expression of miR-127 in proximal cells during the hypoxia condition was indicative of renal ischemia.
• the decrease of its expression early in reoxygenation indicated ischemic damage and its subsequent increase indicated endothelial recovery.
• miR-101 expression was rapidly normalized in reoxygenation where oxygen availability was normalized again and nutrients, although it remained with higher expression levels than in normoxia condition in these rat cells.
• the increased expression of this miRNA in proximal cells during the hypoxia condition was indicative of renal ischemia. Its new 24-hour increase in reoxygenation indicated recovery of the epithelial monolayer.
• FIG. 6 shows and, as in Hk-2 (human tubular) cells, miR-127 increased its expression in the hypoxia condition in which the availability of nutrients and oxygen is restricted, compared to the normoxia condition. .
• the expression of this miRNA was quickly normalized in reoxygenation where oxygen and nutrients were available again.
• the increased expression of this miRNA in proximal cells during the hypoxia condition was indicative of renal ischemia.
• miR-101 increased its expression in the hypoxia condition compared to the normoxia condition.
• the expression of this miRNA remained high in reoxygenation where the availability of oxygen and nutrients was normalized again, and began to normalize at 24h of reoxygenation.
• the increased expression of this miRNA in endothelial cells during the hypoxia condition was indicative of renal ischemia. Its high expression in reoxygenation was associated with a state of endothelial activation (pro-inflammatory), which began to normalize at 24h.
• miR-127 increased its expression in the hypoxia condition in which the availability of nutrients and oxygen was restricted, compared to the normoxia condition.
• the expression of this miRNA remained high in reoxygenation where oxygen and nutrients were available, and began to normalize at 24h of reoxygenation.
• the increased expression of this miRNA in endothelial cells during the hypoxia condition was indicative of renal ischemia. Its high expression in reoxygenation was associated with a state of endothelial activation (pro-inflammatory), which would begin to normalize at 24h.
• the miR-210 increased its expression discreetly in the hypoxia condition compared to the normoxia condition.
• the expression of this miRNA remained high in reoxygenation and sharply decreased its expression at 24h of reoxygenation.
• the increased expression of this miRNA in cells Endothelial during hypoxia condition was indicative of renal ischemia.
• miR-127 and miR-101 its expression in reoxygenation was associated with a state of endothelial activation (pro-inflammatory), which began to normalize at 24h.
• miR-126 increased its expression discreetly in the hypoxia condition in which the availability of nutrients and oxygen is restricted, compared to the normoxia condition.
• EXAMPLE 2 Expression of miRNAs in patients who have been diagnosed with acute renal failure.
• Samples from 50 transplants were analyzed (patients with de novo renal transplant and with different immunosuppression regimens), organized into two groups:
• - Receiver characteristics age, sex, time on dialysis.
• Donor characteristics type of donor (brain death, asystole), age, sex, need for vasoactive drugs and last creatinine.
• the separated serum was collected by centrifugation and aliquoted and stored according to the criteria of the Biobank of the Ramón y Cajal Hospital (in anonymized tubes, with unique code and at -80C).
• Urine samples were collected in Standard urine vials or extracted from the probe reservoir, centrifuged at 2,800 rpm 10 min to remove sediments and other debris, and aliquoted and stored according to the criteria of the Biobank of the Ramón y Cajal Hospital ( in anonymized tubes, with unique code and -80C).
• RNA extraction The processing of serum and urine samples from patients prior to total RNA extraction was as follows: an aliquot of 100-200 microliters of serum or urine, were digested with Proteinase K (0.65 milligrams / milliliter) incubating at 56C , 1 hour. After that, a first extraction with phenol / chloroform (5: 1) was carried out and the aqueous phase was processed using the High Puré miRNA isolation Kit (Roche), following the manufacturer's instructions.
• - AI 10 adult patients operated on a scheduled basis with cardiopulmonary bypass (CEC) and at low risk for the development of ARF, that is, patients with a score of 0 to 2 in the Thakar system5 or 0 to 1 in the simplified SRI6.
• CEC cardiopulmonary bypass

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Wood Science & Technology (AREA)
• Analytical Chemistry (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Pathology (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=43649710

Family Applications (1)

Country Status (12)

Cited By (4)

Families Citing this family (11)

Family Cites Families (4)

• 2009
  • 2009-09-04 ES ES200901825A patent/ES2363661B2/es not_active Expired - Fee Related
• 2010
  • 2010-09-03 AU AU2010291137A patent/AU2010291137A1/en not_active Abandoned
  • 2010-09-03 EP EP10813383A patent/EP2474622A4/en not_active Withdrawn
  • 2010-09-03 WO PCT/ES2010/070579 patent/WO2011027019A2/es not_active Ceased
  • 2010-09-03 CN CN201080044847.XA patent/CN102575294B/zh not_active Expired - Fee Related
  • 2010-09-03 MX MX2012002333A patent/MX2012002333A/es active IP Right Grant
  • 2010-09-03 JP JP2012527360A patent/JP5801809B2/ja not_active Expired - Fee Related
  • 2010-09-03 CA CA2773054A patent/CA2773054A1/en not_active Abandoned
  • 2010-09-03 RU RU2012106742A patent/RU2629591C2/ru not_active IP Right Cessation
  • 2010-09-03 ES ES16150622T patent/ES2710332T3/es active Active
  • 2010-09-03 US US13/394,084 patent/US20120172248A1/en not_active Abandoned
  • 2010-09-03 PT PT16150622T patent/PT3029156T/pt unknown
  • 2010-09-03 EP EP16150622.5A patent/EP3029156B1/en not_active Not-in-force
  • 2010-09-03 IN IN1910DEN2012 patent/IN2012DN01910A/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events